Ozanimod Results Promising in Crohn’s Disease, Ulcerative Colitis, Phase 2 Trial Data Show

Ozanimod Results Promising in Crohn’s Disease, Ulcerative Colitis, Phase 2 Trial Data Show
Celgene recently presented positive data from two Phase 2 studies — the STEPSTONE and TOUCHSTONE studies — for the company’s investigational compound ozanimod (RPC-1063) as a therapy for Crohn’s disease and ulcerative colitis at the World Congress of Gastroenterology at ACG2017  in Orlando, Florida, Oct. 13-18. “The new STEPSTONE findings further validate our hypothesis of ozanimod in Crohn’s disease and the latest data from the TOUCHSTONE study continue to support the potential of ozanimod to provide continued efficacy in ulcerative colitis at 92 weeks,” Terrie Curran, president of Celgene Inflammation and Immunology, said in
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *